Treatment

Cabozantinib (XL184) 60 mg clinical trials

1 indexed studies · 0 currently recruiting

Active not recruitingPHASE4
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
This study looks at two different doses of a drug called cabozantinib for a type of thyroid cancer called medullary thyroid cancer (MTC) that has spread and is getting worse. We want to see if a lower dose works just as well with fewer side effects.
For: Medullary Thyroid Cancer
Australia · Canada · Croatia